Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Fate Therapeutics
(NQ:
FATE
)
3.540
+0.030 (+0.85%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 29, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Fate Therapeutics
< Previous
1
2
3
4
5
6
7
8
9
Next >
Tesla, Meta, NVIDIA And Other Big Losers From Tuesday
September 14, 2022
U.S. stocks closed sharply lower with the Nasdaq Composite dipping more than 5% on Tuesday. Here is the list of some big stocks moving lower in the previous session.
Via
Benzinga
Apple, Amazon, HP And Other Big Losers From Friday
August 29, 2022
U.S. stocks closed sharply lower with the Dow Jones tumbling more than 1,000 points on Friday. Here is the list of some big stocks moving lower in the previous session.
Via
Benzinga
This Healthcare Stock Is Trading Lower By 29%: Here Are 29 Stocks Moving Premarket
August 18, 2022
Gainers
Via
Benzinga
Fate Therapeutics Initiated With Hold Rating - Read Why
July 28, 2022
Via
Benzinga
Why Everbridge Jumped Over 17%; Here Are 90 Biggest Movers From Friday
August 29, 2022
Gainers Micro Focus International plc (NYSE: MFGP) shares surged 92% to close at $6.01 on Friday after the company reached an agreement with OpenText to be acquired for $6 billion.
Via
Benzinga
Despite Durability Questions, BMO Upgraded This Natural-Killer Cell Therapy Oncology Stock
July 12, 2022
Via
Benzinga
Expert Ratings for Fate Therapeutics
July 11, 2022
Within the last quarter, Fate Therapeutics (NASDAQ:FATE) has observed the following analyst ratings:
Via
Benzinga
Recap: Fate Therapeutics Q1 Earnings
May 04, 2022
Fate Therapeutics (NASDAQ:FATE) reported its Q1 earnings results on Wednesday, May 4, 2022 at 04:00 PM. Here's what investors need to know about the announcement.
Via
Benzinga
7 Monkeypox Vaccine Stocks to Buy Before They Shoot Higher
August 17, 2022
These monkeypox stocks could be among the best choices to buy in August. Each can make great investments as government responses ramp up.
Via
InvestorPlace
The 5 Top Stocks Cathie Wood Is Buying Now
August 15, 2022
Cathie Wood's ETFs have performed well following the release of July's CPI report. Recent Cathie Wood stocks include NVTA, TDOC and RBLX.
Via
InvestorPlace
Cathie Wood Is Buying Up Red-Hot Fate Therapeutics (FATE) Stock
August 12, 2022
FATE stock is in focus after Cathie Wood's Ark Invest purchased over 600,000 shares yesterday. This was Ark's first purchase since February.
Via
InvestorPlace
Cathie Wood Scoops Up Over $20M Worth Of Fate Therapeutics Shares, Dumps More Twitter Stock
August 12, 2022
Cathie Wood-led Ark Investment Management has bought 628,060 shares of clinical-stage biopharmaceutical company Fate Therapeutics Inc. (NASDAQ: FATE) through two of the firm’s exchange-traded funds...
Via
Benzinga
Earnings Scheduled For February 28, 2022
February 28, 2022
Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter. • Praxis Precision Medicine (...
Via
Benzinga
This Technology Stock Jumped 55% Following Q2 Results; Here Are 96 Biggest Movers From Yesterday
August 17, 2022
Gainers Eargo, Inc. (NASDAQ: EAR) jumped 77.2% to close at $2.02. The FDA finalized rule enabling access to over-the-counter hearing aids.
Via
Benzinga
7 Small-Cap Stocks to Buy Before the Bull Market Returns
August 07, 2022
These small-cap stocks to buy before the bull market returns have underperformed the market, but have immense potential for future gains.
Via
InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
August 04, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial
August 03, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 28, 2022
July 28, 2022
Via
Benzinga
7 Cathie Wood Stocks Trading at a Discount Right Now
July 26, 2022
These 7 Cathie Wood stocks are the best choices to buy in June. COIN, FATE, NTLA, MELI, TDOC, TSLA, and ZM can make excellent investments.
Via
InvestorPlace
Beyond Meat, Canoo, Veru And More: 12 Short Squeeze Candidates To Watch
July 20, 2022
One of the most powerful tradable market events is a short squeeze, so traders are always on the lookout for the next short squeeze candidate. S3 Partners analyst Ihor Dusaniwsky has just released a...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 12, 2022
July 12, 2022
Upgrades
Via
Benzinga
7 Small-Cap Stocks to Buy in July 2022
July 04, 2022
These are the best small-cap stocks to buy for July 2022. ARCH, AVUV, CEIX, COUR, DVAX, FATE, and TENB can make great investments.
Via
InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For July 11, 2022
July 11, 2022
Upgrades
Via
Benzinga
Will Another Enlivex Innovation Break The Glass Ceiling For Solid Tumor Treatments?
June 14, 2022
Cell therapy — the use of stem cells and various engineered immune cells to target difficult-to-treat diseases like cancer and autoimmune conditions — has arguably been one of the big breakthroughs in...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 3, 2022
June 03, 2022
Via
Benzinga
The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints
May 04, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
What 4 Analyst Ratings Have To Say About Fate Therapeutics
March 04, 2022
Within the last quarter, Fate Therapeutics (NASDAQ:FATE) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total...
Via
Benzinga
Fate Therapeutics: Q4 Earnings Insights
February 28, 2022
Fate Therapeutics (NASDAQ:FATE) reported its Q4 earnings results on Monday, February 28, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings...
Via
Benzinga
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
February 27, 2022
Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first...
Via
Benzinga
Fate Therapeutics's Earnings: A Preview
February 25, 2022
Fate Therapeutics (NASDAQ:FATE) is set to give its latest quarterly earnings report on Monday, 2022-02-28. Here's what investors need to know before the announcement. Analysts...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.